NCT07160075RecruitingPhase 4
HIV Prevention With PrEP Among People on Opioid Replacement Therapy
Improving Access to HIV Pre-exposure Prophylaxis: Implementation and Evaluation of Innovative HIV Prevention Services Among Persons on Opioid Replacement Therapy in Western Canada: Prospective, Implementation Study
Source: ClinicalTrials.gov · Last updated 7 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 350 (estimated)
- First submitted
- 18 Aug 2025
- Start date
- Aug 2025
- Primary completion date
- Sept 2026
- Lead sponsor
- Cara Spence
- Diseases
- HIV
- NCT number
- NCT07160075
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 350
- From Aug 2025 to the primary completion date, Sept 2026
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Deemed appropriate by a clinician for HIV Post-Exposure Prophylaxis at the time of screening or enrollment
Lab values
- Creatine clearance \<30 mL/min or any medical condition or medication known to be contraindicated with the use of Emtricitabine/Tenofovir Alafenamide (F/TAF) or Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
Other
- Taken PrEP within the last 24 hours at the time of screening or enrollment
Who the study is looking for
- HIV negative
- Ongoing behaviors with potential HIV exposure as assessed by a clinician
- Regularly engaged with their respective OAT program at least 3 days a week for the past 2 weeks
- Report willingness to return for follow-up visits
Age in the registry: 16 years to - · Sex: All · Accepts healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sheldon M. Chumir Health Centre Coordinator of this site? Confirm its status | Calgary | Canada | Not yet recruiting |
| Queen City Wellness Pharmacy Coordinator of this site? Confirm its status | Regina | Canada | Not yet recruiting |
| Meadowgreen Pharmacy Coordinator of this site? Confirm its status | Saskatoon | Canada | Recruiting |
| Mayfair Drugs Pharmacy Coordinator of this site? Confirm its status | Saskatoon | Canada | Recruiting |
| The Medicine Shoppe Pharmacy Coordinator of this site? Confirm its status | Saskatoon | Canada | Recruiting |
| Pharmasave Riversdale Pharmacy Coordinator of this site? Confirm its status | Saskatoon | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.